Clinical Trial

Beta-Adrenergic Modulation of Drug Cue Reactivity

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-10-18; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2024-12-05
Trial Details
NCT Number NCT05587361
Lead Sponsor University of Oklahoma
Collaborators: Oklahoma State University Center for Health Sciences, Duke University, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Conditions Tobacco Use Disorder, Nicotine Dependence, Cigarette Smoking
Enrollment 80 participants
Start Date 2024-11-26
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-28